Conditions pregnant, healthy females, healthy male newborns
Sponsor Hadassah Medical Organization
Start date November 2008
End date December 2020
Trial size 1 participant
Trial identifier NCT00801372, 0522-08- HMO-CTIL


Induced pluripotent stem cells potentially may be useful in the future as an unlimited source of cells for transplantation.

The major goal of the project is to develop human iPS cells from existing lines of fibroblasts that were originally donated as clinical grade feeders for the development of clinical grade hESCs. The clinical grade feeders were developed from aborted fetuses, foreskin and umbilical cord.

Recruiting in the following locations…

United States No locations recruiting
Other countries Israel

Study Design

Observational model case-control
Time perspective prospective
Pre-existing fibroblast donors for hESC derivation project

Eligibility Criteria

All participants at least 18 years old.

Inclusion Criteria: - healthy, older than 18 Exclusion Criteria: - non healthy, younger than 18

Additional Information

Official title Use of Existing Fibroblast Cells to Convert to Induced Pluripotent Stem Cells
Description The potential to reprogram somatic cells into an embryonic state raises multiple basic research questions related both to the process of reprogramming and the properties of iPS cells. We will use various approaches to study the molecular mechanisms and processes that occur during reprogramming. We will use various experimental systems to characterize and study the properties of the iPS cells, their biology, developmental potential, capability to give rise to functional differentiated progeny etc. The clinical grade donated feeders used in this project were developed under GMP conditions using animal-free reagents. For potential future clinical applications, the iPS cells will be developed under GMP conditions, using reagents and methods that will be acceptable for clinical applications.
Trial information was received from ClinicalTrials.gov and was last updated in February 2017.
Information provided to ClinicalTrials.gov by Hadassah Medical Organization.